Movement Alert|Kodiak Sciences Inc. Falls 4.15% in Regular Trading, Q3 loss widened and EPS missed expectations

Market Focus11-13

On November 13, Kodiak Sciences Inc. fell 4.15% in Regular Trading, trading at $103.74 per share, with turnover of $3.3317 million.

The move followed the company’s quarterly results, with the market focusing on a wider net loss, higher research and development spending, and earnings that came in slightly below expectations.

Kodiak Sciences Inc. reported third-quarter EPS of $1.05 loss, versus an expected $1.01 loss in one market update, while quarterly net loss widened 8% year over year to $66.22 million. Research and development expense rose 16% to $58.3 million, driven by increased clinical and manufacturing activities. The company said its multi-indication biologics license application for Zenkuda remains planned for the fourth quarter, and a separate analyst note later raised the price target to $150 from $120, but the immediate trading reaction appeared centered on the quarter’s loss and cost pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment